Amid reports of a US Congress probe against India's largest drug maker Ranbaxy Laboratories, data show that many leading multinational companies such as Pfizer, GlaxoSmithKline, Novartis and Merck are also under the scanner of the US drug regulator, for more or less similar violations as Ranbaxy is alleged to have committed.
On the macroeconomic data front, PMI data on manufacturing and services sector will also influence trading
Only a couple of specialty wire services in the US picked up this news; the mainstream press ignored what appears to be a marked -- and dramatic shift -- in the approach to drug discovery. What we are seeing is the first big bang contribution to open source drug discovery, an initiative to rope in researchers, universities and companies to make drug breakthroughs less expensive and time-consuming.
Of the 16 FMCG firms, 12 companies saw an increase in their respective foreign institutional investors holding in three months ended September 2013 over the year-ago period, while the remaining four witnessed a decline in FIIs stake, according to a report by A C Choksi Share Brokers.
India's leading drug maker Ranbaxy Laboratories is likely to announce a drug discovery research tie-up with US drug manufacturer Merck soon. Ranbaxy's ongoing research collaboration with GSK also relates to the pre-clinical trial phase of the new drug, with significant milestone payment and post-commercialisation royalty possibilities. Ranbaxy's decision to de-merge its research operations was intended at having more collaborative research programmes involving foreign firms.
The US-based lubricant major has topped the survey with a 13 per cent market share in 2007, a two per cent lead over its nearest competitor which Shell did not identify. Shell managed to sustain growth in Western Europe where overall demand for lubricants dipped. It was able to retain its market lead of 12 per cent in the US.
GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
FMCG moves fast, while real estate yields ground and metals lose their lustre. The star of 2008 so far has been Hindustan Unilever; the multinational FMCG player has actually gained 20.45 per cent between January 1, 2008 and December 24, 2008.
Though breast cancer is the most common cancer in women, but can rarely occur in males, because of the presence of mammary tissue in males.
Pharma major GlaxoSmithKline and software giant Tata Consultancy Services on Tuesday signed a 'multi-year, multi-million dollar' contract to set up a global drug development support centre in Mumbai.
The plant and associated facilities focus on manufacturing or packaging Amoxicilin-based products, which include semi-synthetic penicillin
Ranbaxy Laboratories has reached an agreement with GlaxoSmithKline on the litigation over the patent validity of GSK's anti-viral drug Valtrex (Valacyclovir Hydrochloride).
Wockhardt's US subsidiary, Wockhardt USA, has launched Ondansetron injection in the United States on December 26.
The Delhi high court had earlier allowed Indian pharma major Wockhardt to sell its Ace Proxyvon tablets, which is a mixture of three salts -- aceclofenac, paracetamol and rabeprazol -- a combination that is banned.
Businesses across the world consider efficient delivery of shipments to be a growth driver, and IoT-based start-up Roambee fills this need with real-time reports to businesses using tracking data.
GlaxoSmithKline Plc has withdrawn its patent application in India for anti-AIDS drug Combivir, which has been facing opposition from activists.
Tata Consultancy Services along with Bharti Televentures and National Thermal Power Corp was on Friday adjudged among the best employers in India by leading global human resources management firm Hewitt Associates.
Foreign multinational drug makers, barring GlaxoSmithKline Pharmaceuticals, continue to have a miniscule presence in the domestic market even after the product patent regime came into being.
GlaxoSmithKline Pharmaceuticals Limited is expanding its clinical trial data management, analyses and reporting activities in India where it plans to double the headcount depending on business needs.
In view of Prime Minister Narendra Modi observing the Navratri fast during his United States visit, the White House on Wednesday said this is unlikely to be an issue as they respectfully accommodate the practices of visitors.
Names such as Danone, Dabur, Mondelez and Abbott Healthcare have also figured on the list of suitors.
Having moved into original research, they have attracted overseas professionals looking to come back, some nudged by MNCs' narrowing research.
The government on Wednesday said Indian drug makers Ranbaxy and Cipla have approached it for assistance in manufacturing Tamiflu to fight bird flu
Adani Exports and GlaxoSmithKline Consumer were the only two A-group stocks that ended in the positive territory.
Most foreign drug makers have 100% subsidiaries in India, apart from their listed arms.
The organisers of the men's tour will unveil a partnership deal with a pharmaceutical giant on Tuesday to provide approved nutritional supplements to players next season.\n
SAS, global leaders in business intelligence solutions, on Friday announced setting up of its largest research and development centre in Pune, as it expects the Indian market to grow by 27 per cent and generate $87.4 billion worth business by 2009.
Take the Rediff Business Quiz and see if you know which are the world's top steel, pharma, wine comapnies.
In a major relief to Glaxo SmithKline Pharmaceuticals Ltd, the Delhi high court on Tuesday protected its popular preparation under the brand name OSTOCALCIUM.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances